C-reactive protein: Risk factor, biomarker and/or therapeutic target?La protéine C-réactive : Facteur de risque, biomarqueur ou cible thérapeutique ?
References (30)
- et al.
The metabolic syndrome – a new worldwide definition
Lancet
(2005) - et al.
Metabolic syndrome and risk of cardiovascular disease: A meta-analysis
Am J Med
(2006) - et al.
Transgenic human CRP is not pro-atherogenic, pro-atherothrombotic or proinflammatory in apoE-/- mice
Atherosclerosis
(2008) - et al.
Effect of intensive lipid-lowering therapy on mortality after acute coronary syndrome (a patient-level analysis of the Aggrastat to Zocor and Pravastatin or Atorvastatin Evaluation and Infection Therapy – Thrombolysis in Myocardial Infarction 22 trials)
Am J Cardiol
(2007) - et al.
Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: A prospective study of the JUPITER trial
Lancet
(2009) - et al.
2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult – 2009 recommendations
Can J Cardiol
(2009) - et al.
The Residual Risk Reduction Initiative: A call to action to reduce residual vascular risk in patients with dyslipidemia
Am J Cardiol
(2008) - et al.
C-reactive protein: A critical update
J Clin Invest
(2003) - et al.
Levels of C-reactive protein associated with high and very high cardiovascular risk are prevalent in patients with rheumatoid arthritis
PLoS One
(2009) Preventive cardiology: Move over LDL-C, hello CRP?
Can J Cardiol
(2004)
Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein
N Engl J Med
(2008)
Non-HDL cholesterol, apolipoproteins A-I and B-100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women
JAMA
(2005)
High-sensitivity C-reactive protein and coronary heart disease in a general population of Japanese: The Hisayama study
Arterioscler Thromb Vasc Biol
(2008)
C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease
New Engl J Med
(2004)
Novel and conventional biomarkers for prediction of incident cardiovascular events in the community
JAMA
(2009)
Cited by (77)
Socioeconomic Status and Inflammation in Women with Early-stage Breast Cancer: Mediation by Body Mass Index
2022, Brain, Behavior, and ImmunityDietary fiber: a functional food ingredient with physiological benefits
2020, Dietary Sugar, Salt and Fat in Human HealthAcidic pH promotes oxidation-induced dissociation of C-reactive protein
2018, Molecular ImmunologyLow-grade inflammation markers in children and adolescents: Influence of anthropometric characteristics and CRP and IL6 polymorphisms
2016, CytokineCitation Excerpt :According to Silva and Lacerda [39], CRP is not only an inflammatory marker but also actively participates in the atherogenic process and adds prognostic value to the traditional risk factors, and may be relevant in the identification of individuals at risk for future cardiovascular events, even in individuals who would be categorized as being low risk. In addition to acute inflammation, serum concentrations of CRP and IL-6 depend primarily on the adiposity index, which was associated with the pro-inflammatory state in various studies [2–40]. Thus, obese individuals tend to have high concentrations of CRP and IL-6 compared with normal weight subjects [28].
Increased C-reactive protein and decreased Interleukin-2 content in serum from obese individuals with or without insulin resistance: Associations with leukocyte count and insulin and adiponectin content
2016, Diabetes and Metabolic Syndrome: Clinical Research and Reviews
Copyright © 2010 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.